The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Ixekizumab Improves Outcomes of Ankylosing Spondylitis

Ixekizumab Improves Outcomes of Ankylosing Spondylitis

November 5, 2018 • By Will Boggs, MD

  • Tweet
  • Email
Print-Friendly Version / Save PDF

NEW YORK (Reuters Health)—Ixekizumab improves signs and symptoms in patients with radiographic axial spondyloarthritis (ankylosing spondylitis), according to results from the COAST-W study.

You Might Also Like
  • FDA Approves Ixekizumab for Treating Active Ankylosing Spondylitis
  • Interleukin 17 Inhibitors Promising in Ankylosing Spondylitis Patients
  • Phase 3 Results for Ixekizumab Promising in Patients with Non-Radiographic Axial Spondyloarthritis
Explore This Issue
December 2018

“Ankylosing spondylitis is a chronic and debilitating disease, and I have a large number of patients who have failed TNF inhibitors,” says Dr. Atul Deodhar from Oregon Health and Science University, Portland.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

“There’s a need for more options, specifically for this difficult-to-treat patient population. If ixekizumab is approved for the treatment of ankylosing spondylitis, it would give physicians another option for their patients,” he tells Reuters Health by email.

Axial spondyloarthritis is commonly treated with tumor necrosis factor (TNF) inhibitors, but as many as 40% of patients do not achieve adequate disease control or symptom relief with TNF inhibitors. Ixekizumab is a monoclonal antibody that selectively targets IL-17A, which has been implicated in the immunopathology of axial spondyloarthritis.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Dr. Deodhar and colleagues investigated the efficacy and safety of ixekizumab (vs. placebo) in 316 patients with active radiographic axial spondyloarthritis with previous inadequate response or intolerance to one or two TNF inhibitors.

The proportion of patients who achieved the primary endpoint of 40% improvement in Assessment of SpondyloArthritis International Society (ASAS40) at Week 16 was significantly higher among patients treated with 80 mg ixekizumab every two weeks (30.6%) or every four weeks (25.4%) than among patients treated with placebo (12.5%), the researchers report in Arthritis & Rheumatology, online Oct. 20.1

The findings were also presented at the 2018 ACR/ARHP Annual Meeting Oct. 19–24 in Chicago.

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

“If I’m a patient, I want greater improvement in my symptoms, and the ASAS40 measure used in this study was very stringent,” Dr. Deodhar says.

More patients in the ixekizumab groups also achieved 20% improvements in ASAS (ASAS20) at 16 weeks (46.9% and 48.2% vs. 29.8%).

Compared with placebo patients, ixekizumab patients had significant improvements in measures of disease activity, function and quality of life.

Spinal MRI and systemic inflammation improved significantly in patients treated with ixekizumab.

More ixekizumab than placebo patients reported treatment emergent adverse events, most of which were mild or moderate in severity. Serious adverse events occurred with similar frequency across treatment arms.

“The current results support ixekizumab as a treatment option in patients with radiographic axial spondyloarthritis and prior inadequate response or intolerance to TNF inhibitors,” the researchers conclude.

Eli Lilly and Company funded the study, employed several authors and financial ties to several more, including Dr. Deodhar.


Reference

  1. Deodhar A, Poddubnyy D, Pacheco-Tena C, et al. Efficacy and safety of ixekizumab in the treatment of radiographic axial spondyloarthritis: 16 week results of a phase 3 randomized, double-blind, placebo controlled trial in patients with prior inadequate response or intolerance to tumor necrosis factor inhibitors. Arthritis Rheumatol. 2018 Oct 20. doi: 10.1002/art.40753. [Epub ahead of print]

Pages: 1 2 | Single Page

Filed Under: Biologics & Biosimilars, Drug Updates, Spondyloarthritis Tagged With: Ankylosing Spondylitis, ixekizumab, TNF inhibitorIssue: December 2018

You Might Also Like:
  • FDA Approves Ixekizumab for Treating Active Ankylosing Spondylitis
  • Interleukin 17 Inhibitors Promising in Ankylosing Spondylitis Patients
  • Phase 3 Results for Ixekizumab Promising in Patients with Non-Radiographic Axial Spondyloarthritis
  • Ustekinumab Improves Spondylitis in Patients with Psoriatic Arthritis

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2022 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)